Stock INFI.Q INFINITY PHARMACEUTICALS, INC.
Add to a list

Infinity Pharmaceuticals, Inc. Stock

Stocks

INFI.Q

US45665G3039

Environmental Services & Equipment

OTC Markets Traded
End-of-day quote
OTC Markets
2026-10-30 		5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Infinity Pharmaceuticals, Inc. -.--% -
24-03-25 Infinity Pharmaceuticals, Inc. Went Out of Business CI
24-03-06 Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc. CI

Valuation: Infinity Pharmaceuticals, Inc.

Market Cap 227K 203K 186K 169K 318K 21.49M 326K 2.22M 894K 11.34M 852K 833K 35.96M P/E 2021
-4.25x
P/E 2022 -1.11x
Enterprise Value 11.26M 10.06M 9.24M 8.39M 15.76M 1.07B 16.16M 110M 44.38M 563M 42.27M 41.37M 1.78B EV / Sales 2021
91.8x
EV / Sales 2022 23.4x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
* Estimated data More valuation ratios

Chart: Infinity Pharmaceuticals, Inc.

Dynamic Chart

Latest news: Infinity Pharmaceuticals, Inc.

24-03-25 Infinity Pharmaceuticals, Inc. Went Out of Business CI
24-03-06 Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc. CI
24-02-21 Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc. CI
24-02-14 An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q). CI
24-02-12 First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc. CI
24-02-01 Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc. CI
24-01-25 First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc. CI
24-01-10 Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc. CI
24-01-07 Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc. CI
23-10-23 Bidding Procedure Approved for Infinity Pharmaceuticals, Inc. CI
23-10-02 Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc. CI
23-09-29 Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board CI
23-09-29 INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI… RE
More news

Analysts' recommendations: Infinity Pharmaceuticals, Inc.

23-02-24 Piper Sandler Downgrades Infinity Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $0.30 From $3 MT
22-11-15 B. Riley Downgrades Infinity Pharmaceuticals to Neutral From Buy, Lowers PT to $1.50 From $3; Moves to Sidelines Until Partner Helps Advance Eganelisib MT
22-08-15 JonesTrading Downgrades Infinity Pharmaceuticals to Hold From Buy MT
22-08-10 B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating MT
22-05-23 Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $3 from $4, Keeps Overweight Rating MT
More recommendations

Press Releases: Infinity Pharmaceuticals, Inc.

24-05-14 Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) AQ
23-12-05 Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others. AQ
23-09-29 Infinity Pharmaceuticals : Bankruptcy - Form 8-K PU
23-08-18 INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm BU
23-07-25 Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan BU
More press releases

News in other languages: Infinity Pharmaceuticals, Inc.

15-01-08 BIND Therapeutics : Les valeurs à suivre sur les marchés américains.
15-01-08 USA-Les valeurs à suivre à Wall Street
More news

Price Extremes

1 week 0
Extreme 1.0E-6
 0
1 month 0
Extreme 1.0E-6
 0
Current year 0
Extreme 1.0E-6
 0
1 year 0
Extreme 1.0E-6
 0
3 years 0
Extreme 1.0E-6
 0.02
5 years 0
Extreme 1.0E-6
 2.81
10 years 0
Extreme 1.0E-6
 5.98
More quotes

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap. Importance
9/8/23
Adelene Perkins
Exercice

Chief Executive Officer

1,946,462 2.1446%
8/2/22
Stéphane Peluso
Exercice

Chief Technology Officer

114,994 0.1290%
6/16/22
David Beier
Free

Director

45,000 0.0505%
Transaction History

Other Environmental Services & Equipment

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
INFINITY PHARMACEUTICALS, INC. Stock Infinity Pharmaceuticals, Inc.
-.--%-.--%-.--%-99.97% 90
WASTE MANAGEMENT, INC. Stock Waste Management, Inc.
-1.28%-0.48%+19.26%+39.58% 93.31B
REPUBLIC SERVICES, INC. Stock Republic Services, Inc.
-1.26%+3.06%+18.31%+58.27% 73.99B
WASTE CONNECTIONS, INC. Stock Waste Connections, Inc.
-0.80%+2.58%+12.61%+40.10% 46.7B
VERALTO CORPORATION Stock Veralto Corporation
+0.54%+12.72%+17.57%+64.29% 28.28B
GFL ENVIRONMENTAL INC. Stock GFL Environmental Inc.
-0.45%+1.25%+4.15%+56.70% 19.96B
CLEAN HARBORS, INC. Stock Clean Harbors, Inc.
-0.43%-5.79%+41.25%+90.69% 15.55B
TETRA TECH, INC. Stock Tetra Tech, Inc.
-0.40%+6.89%+23.70%+28.61% 10.09B
DONALDSON COMPANY, INC. Stock Donaldson Company, Inc.
+0.67%+0.59%+1.68%+44.10% 9.96B
CASELLA WASTE SYSTEMS, INC. Stock Casella Waste Systems, Inc.
-1.70%+2.69%+8.46%+21.61% 6.12B
Average -0.51%+2.15%+14.70%+34.40% 30.4B
Weighted average by Cap. -0.85%+1.94%+17.34%+49.67%
See all sector performances

Financials

2021 2022
Net sales 1.86M 1.66M 1.52M 1.38M 2.6M 176M 2.67M 18.2M 7.32M 92.9M 6.97M 6.82M 294M 2.59M 2.32M 2.13M 1.93M 3.63M 246M 3.72M 25.4M 10.22M 130M 9.73M 9.52M 411M
Net income -45.26M -40.44M -37.14M -33.73M -63.35M -4.29B -64.94M -443M -178M -2.26B -170M -166M -7.17B -44.37M -39.64M -36.41M -33.07M -62.1M -4.2B -63.66M -435M -175M -2.22B -167M -163M -7.03B
Net Debt -29.67M -26.5M -24.35M -22.11M -41.52M -2.81B -42.56M -291M -117M -1.48B -111M -109M -4.7B 11.04M 9.86M 9.06M 8.22M 15.44M 1.05B 15.83M 108M 43.48M 552M 41.42M 40.53M 1.75B
* Estimated data More financial data

Company Profile

Logo Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Employees
30
Sector
Environmental Services & Equipment
More about the company

Quotes

Date Price Change Volume

End-of-day quote OTC Markets

More quotes
  1. Stock Market
  2. Stocks
  3. INFI.Q Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong